Nicolás Martínez‐Calle
A5037565105- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Glioma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Acute Myeloid Leukemia Research
- Lung Cancer Treatments and Mutations
- Venous Thromboembolism Diagnosis and Management
- Advanced Breast Cancer Therapies
- Cancer-related gene regulation
- Epigenetics and DNA Methylation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Immunodeficiency and Autoimmune Disorders
- Kruppel-like factors research
- Cutaneous lymphoproliferative disorders research
- Atrial Fibrillation Management and Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Parasites and Host Interactions
- Histone Deacetylase Inhibitors Research
- Multiple and Secondary Primary Cancers
- Moyamoya disease diagnosis and treatment
Nottingham University Hospitals NHS Trust
2018-2025
Clinica Universidad de Navarra
2012-2024
University of Nottingham
2021-2023
National Institute of Allergy and Infectious Diseases
2023
National Institutes of Health
2023
National Health Service
2021-2023
Universidad de Navarra
2012-2020
Centro de Investigación Biomédica en Red de Cáncer
2019-2020
Navarre Institute of Health Research
2018
Office of Infectious Diseases
2013
Chronic myelomonocytic leukemia (CMML) has recently been associated with a high incidence of diverse mutations in genes such as TET2 or EZH2 that are implicated epigenetic mechanisms. We have performed genome-wide DNA methylation arrays and mutational analysis TET2, IDH1, IDH2, JAK2 group 24 patients CMML. 249 were differentially methylated between CMML controls. Using Ingenuity pathway analysis, we identified enrichment gene network centered around PLC, JNK ERK suggesting these pathways,...
Summary Central nervous system (CNS) relapse following R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) occurs in 2–5% of patents with diffuse large B‐cell lymphoma (DLBCL). Many patients aged ≥70 years are unsuitable for high‐dose methotrexate (HDMTX) prophylaxis and therefore often receive stand‐alone intrathecal prophylaxis. The CNS international prognostic index (CNS‐IPI) is a clinical risk score that has not specifically been validated elderly patients. value...
Summary The MATRix chemoimmunotherapy regimen is highly effective in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system (PCNSL). However, nothing known about its feasibility and efficacy everyday practice, where are more often older/frailer than those enrolled clinical trials. We conducted a retrospective study addressing tolerability/efficacy 156 consecutive PCNSL treated outside trial. Median age ECOG Performance Status considered were 62...
Delayed lymphocyte and T-cell immune reconstitution following bendamustine-rituximab (BR) for indolent non-Hodgkin lymphoma (iNHL) has been described, but no information is available chronic lymphocytic leukaemia (CLL). We present a population-based retrospective analysis of risk infection BR. Outcomes included timing/correlates CD4+ recovery ≥grade 3 infections. Consecutively treated patients (1 April 2014 to 31 January 2017) were (n = 295),with median age 65 years (range 33-92); 57% 1st...
Abstract High-dose methotrexate (HD-MTX) is increasingly used as prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of central nervous system (CNS) relapse. However, there limited evidence to guide whether intercalate HD-MTX (i-HD-MTX) between R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone given 21-day intervals) or give it the end treatment (EOT) R-CHOP-21. We conducted a retrospective, multicenter analysis 334 DLBCL who...
Recent changes to the commissioned regimens and COVID-19 pandemic necessitate an update of 2018 British Society Haematology guidance on chronic lymphocytic leukaemia (CLL).1 Here we discuss: (1) considerations prior treatment; (2) front-line treatment recommendations; (3) management relapsed or refractory disease; (4) intolerance Bruton tyrosine kinase inhibitors (BTKi); (5) for vaccinations prophylaxis. We focus particularly therapies approved use in UK at time writing. Guidance initial...
Summary Data on older patients with primary central nervous system lymphoma (PCNSL) are scarce. Comorbidities and performance status frequently compromise outcomes in this group. Medical records for consecutive ≥65 years ( n = 244) PCNSL diagnosed 2012–2017 from 14 UK centres were retrospectively reviewed. Of these 192 received methotrexate (MTX)‐based treatment. Patients categorised based clinician's treatment choice into ‘palliative’ 52), ‘less intensive: MTX ± rituximab alkylators’ 74)...
Abstract Background The increasing incidence of diffuse large B‐cell lymphoma (DLBCL) in ageing populations places a significant burden on healthcare systems. Co‐morbidity, frailty, and reduced organ physiological reserve contribute to treatment‐related complications. optimal dose intensity R‐CHOP optimize outcome across different ages with variable frailty comorbidity is unclear. Objectives Methods We examined the influence intended (IDI) relative (RDI) combination cyclophosphamide...
Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed validated novel index specific for BL to aid risk stratification, interpretation of trials, targeted development treatment approaches.We derived the International Prognostic Index (BL-IPI) from real-world data set adult patients with treated immunochemotherapy in United States between 2009 2018, identifying candidate variables that showed strongest association progression-free...
Abstract Despite the development of novel therapies for acute myeloid leukemia, outcomes remain poor most patients, and therapeutic improvements are an urgent unmet need. Although treatment regimens promoting differentiation have succeeded in promyelocytic their role other leukemia subtypes needs to be explored. Here we identify characterize two lysine deacetylase inhibitors, CM-444 CM-1758, exhibiting capacity promote all at low non-cytotoxic doses, unlike commercial histone inhibitors....
Abstract Infection-related morbidity and mortality are increased in older patients with diffuse large B-cell lymphoma (DLBCL) compared population-matched controls. Key predictive factors for infection-related hospitalization during treatment rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) deaths as a result of infection after R-CHOP remain incompletely understood. For this study, 690 consecutively treated age 70 years or who received full-dose attenuated-dose...
Summary Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front‐line ‘attenuated’ or low‐intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report of attenuated 95 with MCL across 19 centres the UK and Ireland considered for full‐dose rituximab‐bendamustine rituximab‐cyclophosphamide, doxorubicin, vincristine, prednisolone (R‐CHOP). Regimens examined were (R‐CVP) ( n = 19), dose‐attenuated R‐CHOP...
In this study we interrogated the DNA methylome of myelofibrosis patients using high-density methylation arrays. We detected 35,215 differentially methylated CpG, corresponding to 10,253 genes, between and healthy controls. These changes were present both in primary secondary myelofibrosis, which showed no differences them. Remarkably, most CpG located outside gene promoter regions significant association with enhancer regions. This aberrant hypermethylation was negatively correlated...